T-cell receptor and chimeric antigen receptor in solid cancers: current landscape, preclinical data and insight into future developments

Purpose of reviewThe remarkable and durable clinical responses seen in certain solid tumours using checkpoint inhibitors and in haematological malignancies using chimeric antigen receptor (CAR) T therapy have led to great interest in the possibility of using engineered T-cell receptor (TCR) and CAR